Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
HENDERSON, Nev. - P3 Health Partners Inc. (NASDAQ: PIII), a physician-led health management company currently valued at $72.84 million, announced its preliminary financial outlook for the fiscal year ending December 31, 2025, aiming for profitability with expected revenues ranging from $1.350 billion to $1.500 billion and an Adjusted EBITDA between negative $35 million and $5 million. According to InvestingPro data, the company has demonstrated strong revenue growth of 25.38% in the last twelve months, despite current profitability challenges.
The company, which is in the midst of implementing $130+ million EBITDA growth initiatives, expressed confidence in achieving its profitability target for 2025. InvestingPro analysis reveals the company is currently burning through cash with an EBITDA of -$166.08M, highlighting the importance of these initiatives. P3 Health Partners’ CEO Aric Coffman stated that the company’s progress on growth initiatives and support from shareholders are key factors in this optimistic outlook. Coffman also revealed that P3 plans to issue comprehensive guidance for 2025 concurrent with its fourth quarter 2024 earnings report, scheduled for March 28, 2025.
In addition to its financial projections, P3 Health Partners is currently negotiating a proposed financing transaction with its largest shareholder. The transaction involves a $30 million unsecured promissory note and warrants, with terms similar to those of a financing deal completed in December 2024. The completion of this deal is contingent upon the approval of an independent committee of directors and the finalization of definitive documentation.
P3 Health Partners, founded by physicians, operates a network of over 3,100 affiliated primary care providers and manages patient care in 24 counties across four states. The company focuses on value-based care coordination, administrative services, and improving patient outcomes while lowering healthcare costs. It supports primary care providers to enhance the patient experience within the healthcare system.
The company’s financial measures include non-GAAP metrics like Adjusted EBITDA, which excludes certain items to provide a clearer picture of operating performance. P3 Health Partners also monitors "at-risk members," a key performance metric that represents the number of Medicare members under capitation arrangements.
Investors are cautioned that actual results for 2025 may differ materially from projections due to various factors, including market conditions and regulatory changes. The company does not assume any obligation to update these estimates. Analyst targets for the stock currently range from $0.25 to $1.00, with InvestingPro’s comprehensive analysis indicating the stock may be undervalued at current levels. For deeper insights into P3 Health Partners’ financial health and growth potential, investors can access the detailed Pro Research Report, available as part of the extensive analysis of 1,400+ US stocks on InvestingPro.
This news is based on a press release statement from P3 Health Partners Inc. and does not constitute an offer to sell securities. The securities discussed may not be registered under the Securities Act of 1933 and may be subject to certain exemptions from registration requirements.
In other recent news, P3 Health Partners has seen several significant developments. The company’s Q3 2024 earnings call revealed a 26% year-over-year revenue increase to $362.1 million, despite an adjusted EBITDA loss of $71 million. This loss was attributed to elevated medical claims and retroactive adjustments. In response, P3 Health Partners has initiated over $130 million in strategic initiatives to enhance contracts, operational discipline, efficiency, and data analytics.
Simultaneously, the healthcare services provider secured a $25 million financing deal to support its working capital needs, according to a recent 8-K filing with the Securities and Exchange Commission. This deal includes a financing agreement, termination of a previous agreement, and creation of new financial obligations.
In terms of analyst notes, DA Davidson adjusted the price target for P3 Health Partners to $60.00, down from the previous $69.00, while maintaining a Buy rating. The adjustment followed the release of the company’s financial guidance for fiscal year 2025, which did not meet analyst expectations. TD Cowen also reduced its price target for P3 Health Partners to $0.25 from $0.90, maintaining a Hold rating on the company’s shares following the release of the company’s third-quarter results. These are the recent developments for P3 Health Partners.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.